Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 1 35 21 versus OVCON 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 1 35 21 versus OVCON 35.
NORTREL 1/35-21 vs OVCON-35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Category C
Category C
Oral Contraceptive
Oral Contraceptive